IRIS
CONSOLARO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.147
Totale 11.147
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 11.147
Totale 11.147
Salva come PNG Salva come JPEG
Città #
Genova 8.887
Rapallo 1.366
Genoa 863
Bordighera 31
Totale 11.147
Salva come PNG Salva come JPEG
Nome #
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 151
Juvenile Idiopathic Arthritis: Diagnosis and Treatment 147
The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 139
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 138
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 131
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 122
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 120
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 118
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 116
Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases 115
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 115
The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 114
Development and testing of reduced joint counts in juvenile idiopathic arthritis. 113
TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis 113
The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 113
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 113
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 113
The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 112
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 112
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 112
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 111
The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 111
The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 111
Advances in biomarkers for paediatric rheumatic diseases 111
Unraveling the phenotypic variability of juvenile idiopathic arthritis across races or geographic areas - Key to understanding etiology and genetic factors? 110
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 110
Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 109
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 109
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 109
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries 109
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. 108
The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 108
The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 108
Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. 107
It is worth including assessment of disease activity state in juvenile arthritis clinical trials. 107
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. 106
Glucocorticoids in juvenile idiopathic arthritis. 106
The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 105
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis 104
Clinical outcome measures in juvenile idiopathic arthritis 104
The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 104
The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 104
The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 104
The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 104
Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016 104
The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 103
The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 103
The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 103
The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 103
The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 102
The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 102
IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis 101
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis 101
The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 100
The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 100
Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis. 99
Filling the Gap: Toward a Disease Activity Tool for Systemic Juvenile Idiopathic Arthritis 99
The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 99
The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 98
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 98
Prevalence of overweight and obesity in 2- to 6-year-old Italian children 96
The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 96
The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 96
Recent therapeutic advances in juvenile idiopathic arthritis 96
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study 96
The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 95
The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 95
The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 95
Defining criteria for disease activity States in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. 94
The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 94
The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 94
The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 94
The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 93
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 93
The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 92
The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 92
The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 92
The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 91
Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. 90
The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 89
Predictors of effectiveness of anakinra in systemic juvenile idiopathic arthritis 89
Paediatric rheumatology: Juvenile idiopathic arthritis--are biologic agents effective for pain? 88
Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop 88
Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. 86
Disease activity and damage in juvenile idiopathic arthritis: Methotrexate era versus biologic era 86
Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). 85
The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 85
The Egyptian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 84
A child with a novel ACAN missense variant mimicking a septic arthritis 83
Optimisation of disease assessments in juvenile idiopathic arthritis. 80
A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis 80
The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 79
The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 79
The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 79
The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 79
Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress. 78
Treating juvenile idiopathic arthritis to target: Recommendations of an international task force 78
Defining criteria for disease activity states in juvenile idiopathic arthritis 77
Ghrelin, insulin sensitivity and postprandial glucose disposal in overweight and obese children 76
Glucocorticoids in paediatric rheumatology 75
Totale 10.128
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.362
article - articoli 35.362
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.724
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019658 0 0 0 0 0 0 0 0 0 0 355 303
2019/20204.398 186 105 94 256 309 588 719 594 513 567 340 127
2020/20211.389 68 157 71 150 76 70 137 135 71 178 70 206
2021/20221.488 72 59 122 119 55 123 61 326 125 175 63 188
2022/20231.632 147 147 21 144 251 274 9 159 276 14 165 25
2023/2024655 35 113 35 110 71 73 89 46 41 35 7 0
Totale 11.644